Articles

Blue oceans, market access and competition - PMLiVE: January 2016

market-access-competition-thumbnail
Requirements for strategic planning within launch optimisation and market access

The pharmaceutical industry continues to innovate and stride ahead. However, in today’s challenging austere climate, those contemplating new product launches need to navigate many financial and competitive obstacles. Innovation is only as good as the commercialisation strategy behind it. So what does austerity mean for the pharmaceutical industry and how can new product launches survive and achieve success?

Read More

Increased Competition in Japan

japan-thought-piece
Is the pharmaceutical industry ready?

Like many developed countries, Japan is facing new financial challenges. The strain of demographic changes, mounting expenses and a stagnant economy mean significant economic and healthcare reforms are underway to meet future needs. However, as new entrants…

Read More

Asian Pricing and Reimbursement

asian-pricing
How to compete and succeed in a rapidly changing market

Growing major trends are emerging across Asian healthcare markets. Rising incomes, increased government healthcare expenditure, higher life expectancies and a surge of chronic illnesses are boosting the demand for pharmaceutical products and services in the region.

Read More

Asian Market Entry - Opportunities and Challenges

asia-market-entry
Asia, a continent of extremes, with great potential for growth

Asia is a continent of diversity. Geographically large, the assortment of cultures, people, disease profiles, and healthcare systems added to the juxtaposition of extreme wealth and extreme poverty,

Read More

Computer Gaming: The Future of Decision-Making for Life Sciences?

computer-gaming-life-science
How can life science brands identify winning strategic decisions when there are so many variables to consider?

One route is via ‘road-testing’ decisions ahead of sign-off under computer game simulated conditions, which offer a risk-free environment in which all the variables have been mapped and considered.

Read More

Can Cinderella Save Us?

deallus-thought-piece
There is hope that companies can safeguard against a new age of medicine

Through the 1980s and 1990s antibiotic development was the pharmaceutical industry’s Cinderella. Coming from humble origins she had made it to the ball and married her prince. However since then things have taken a downward turn for our favourite fairy-story characters and the ugly regulatory and market condition sisters have sent Cinderella back to the shadows of the kitchen. The question now is whether she can make it back to the ball and become our princess once more?

Read More

CI in Pharma: A juxtaposition of Global Perspectives with Regional Realities

deallus-thought-piece
While the pharmaceutical industry is no stranger to the public discourse of Competitive Intelligence and its growing importance, it is, however, a topic traditionally of most interest in Global Headquarters (HQ).

There is a paradox, that even as Pharma companies expand their global reach by growing regional and local affiliates, dedicated CI teams remain a HQ function. But make no mistake, it does not mean that competitor insights play no role outside of US and EU HQ — rather, regional and local stakeholders have different ways of obtaining such insights for their decision-making. The “how”, and “when”, and “what”, however, remain a largely elusive picture.

Read More

Are domestic vaccines manufacturers in ASEAN markets a threat or an opportunity for successful market entry?

deallus-thought-piece
Selling vaccines in the region places commercial considerations alongside humanitarian obligations.

Vaccines are the most cost-effective healthcare intervention, as they prevent disease rather than curing it. Benefits offered to individuals and healthcare systems are clearest in low resource countries, but the healthcare market gap between need and access/affordability also exists in the vaccines field.

Read More

Putin - pharma's friend or foe?

deallus-thought-piece
Assessing the opportunities and challenges for pharmaceutical companies entering the Russian market

Read More

Unraveling China's Healthcare Sector

deallus-thought-piece
How will Chinese health reforms, the tightening of regulations and the emergence of a domestic drug industry impact global pharmaceutical companies?

Read More

Opportunities in the medical devices sector

deallus-thought-piece
Growing medical tourism, a burgeoning hospital sector and increased patient affluence make India an attractive prospect for medical device companies looking for partnerships

The Indian healthcare sector provides a lucrative growth avenue for companies already operating in the region and for new entrants, particularly diagnostic device manufacturers, pharmaceutical companies and health insurance providers.

Read More

The Latin American biosimilar landscape

deallus-thought-piece
Cost containment and safety concerns mean an ongoing tussle between payors and regulators, with the latter gaining the upper hand

Latin America as a region is experiencing an unprecedented period of economic growth and development which is having a direct impact on healthcare in two ways. Firstly, it has allowed the substantial growth of a middle class now capable of accessing private healthcare services.

Read More

South Korea, an eye towards the bio better

deallus-thought-piece
The South Korean government plays an important role in shaping the domestic biopharmaceutical industry

In November 2010, the Ministry of Knowledge & Economy announced unprecedented capital and regulatory support to boost the industry, setting an ambitious target for Korean pharmaceuticals to capture 22 per cent of the global biosimilars market share by 2020.

Read More

China, tipping the balance

deallus-thought-piece
Fueled by changing epidemiology, reimbursement incentives and advancement of the local pharmaceutical industry, the emerging country biosimilar market has been taking an increasingly large share of the global market

So, what lies in store for multinational pharmaceutical companies (MNCs)? What are the real opportunities and risks in entering these markets and how can the former be optimised and the latter minimised?

Read More

Mexico, an appealing destination for clinical trials outsourcing

deallus-thought-piece
Mexico: Regulatory improvements make Mexico an appealing destination for clinical trials outsourcing

Market forces and increasing regulatory oversight have placed substantial pressure on pharmaceutical companies to reduce drug development costs. Clinical trial outsourcing to destinations such as India and China has provided the opportunity to realize significant savings in drug development costs. At the same time, the old R&D model is changing from full in-house development at pharmaceutical companies to a new model driven by small to midsize biotechnology companies that provide promising drug candidates to weakening pipelines.

Read More

An inch of time is an inch of gold for Chinese companies eyeing Western drugs

deallus-thought-piece
An inch of time is worth an inch of gold right now for Chinese biotechnology companies looking to purchase or license Western drugs

While China is rolling in cash, the number of Western firms investing in biotechnology assets continues to consolidate in the wake of the Western financial crisis.

Read More

Braving changing Indonesian tides in the pharmaceutical sector: seizing opportunities amidst local challenges

deallus-thought-piece
Indonesia: Healthcare reforms open up huge potential in the market to companies with a carefully tailored expansion strategy

Indonesia represents one of the most attractive up-and-coming markets for pharmaceutical companies looking to expand across the Asia-Pacific region. As a sizeable population of 234 million that is witnessing a rapid expansion of the middle class, Indonesia is poised to become a key market of growth in this region for the healthcare industry.

Read More